The Food and Drug Administration has launched a new performance-measure initiative that will allow the general public to track how well the agency is doing in meeting key goals.
Called FDA-TRACK, which is short for Transparency, Results, Accountability, Credibility and Knowledge-sharing, the initiative will monitor, collect and analyze data from more than 100 FDA program offices. The performance data will be presented quarterly to FDA senior leadership and made public through the data.gov website by year-end.
“FDA-TRACK will bring the operations of this historically opaque agency into the daylight and help us be even more responsive as we work to protect the public health,” FDA Commissioner Margaret Hamburg said in a news release.
The program, according to the news release, will provide performance measures in four categories: common measures, which focus on agencywide goals applicable to all 100 program offices; center-director measures, which analyze progress on goals set by center leadership such as the director of the Center for Devices and Radiological Health; program measures, which assess progress on program-office goals such as meeting device-approval application review deadlines; and key project measures, which track achievement on projects such as the implementation of a new product-evaluation method.
The FDA-TRACK program is part of a larger transparency initiative being implemented by HHS. That initiative calls for the agency to roll out performance-measure dashboards on 14 health-information data sets by year-end. They will include measures on CMS and FDA activities. The dashboards will be made public and will provide information such as Medicare expenditures and provider-quality assessments, FDA progress on new-product applications and Centers for Disease Control and Prevention information on hospital emergency department trends.